Cargando…
Correction: Correction: Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
Public Library of Science
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9584390/ https://www.ncbi.nlm.nih.gov/pubmed/36264846 http://dx.doi.org/10.1371/journal.pone.0276650 |